A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples